$AEMD

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

U.S. stocks rose midday, with S&P 500 up 1%. Pending home sales increased 0.3% in August. Aethlon Medical (AEMD) surged 390% on merger news. Datasea (DTSS) rose 81% on AI service agreements. Fluence Energy (FLNC) fell 14% after price target cuts. Oil dropped 1.4%, gold up 0.4%. European and Asian markets mixed.

Aethlon Medical (AEMD) rose 390% after announcing a merger with North Immunology, raising $180M. Metalsource Mining (MSM) reported high-grade silver intercepts. VisionWave (VWAV) filed a patent for an AI counter-drone system.

Aethlon Medical (AEMD) surged over 400% after announcing a merger with North Immunology. BioAffinity Technologies (VEEA) also rose following a Hong Kong patent grant for its CyPath Lung diagnostic. Other biotech stocks saw mixed pre-market activity.

Aethlon Medical (AEMD) surged 346% premarket after announcing an all-stock merger with North Immunology, expected to close in Q1 2027. AEMD's P/S ratio is near zero, reflecting market skepticism. The combined entity, North Immunology Inc. (NRTX), is valued at $346.5M. AEMD's GF Score is 19/100, indicating weak financial health.

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis North Immunology’s lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and no

Aethlon Medical (NASDAQ:AEMD) shares surged over 400% in premarket trading after announcing a merger with North Immunology. The all-stock deal includes $180M in financing from investors. The combined entity will trade as NRTX on Nasdaq. North Immunology develops bispecific antibodies for immune diseases, with NOR-101 in development for atopic dermatitis.

Aethlon Medical (AEMD) and North Immunology, a private biotech firm, plan to merge in an all-stock deal. The combined company, trading as NRTX, will focus on developing NOR-101, a bispecific antibody for atopic dermatitis. A $180M private placement will fund operations into 2028. Phase 1a trials are set to start in Q1 2027, with interim data expected by mid-2027 and Phase 1b/2b data in 2028. The transaction is expected to close in Q1 2027, subject to shareholder and regulatory approvals.

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 11, 2026, Aethlon Medical, Inc. (the “Company”) entered into amendments to the employment agreements of James

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.